Search | Page 9 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Clinical Trials Report for September 2015

    ... Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study The primary purpose of this study is ... syndromes (low/int-1 risk) and transfusional iron overload . This study is being conducted by Novartis Pharmceuticals ...

    Page last updated 08/26/2015 - 1:05pm.

  2. Aristoteles Giagounidis, MD

    ... in myelodysplastic syndromes, deferasirox in iron overload , eltrombopag , romiplostim, and rituximab in idiopathic ...

    Page last updated 01/20/2012 - 3:30pm.

  3. Financial Resources

    ... financial assistance to patients suffering from chronic Iron Overload and MDS who need specialty medications. Good Days realizes that a ...

    Page last updated 08/26/2015 - 10:47am.

  4. Overlap Syndromes: When PNH Appears with Aplastic Anemia

    ... mind is that patients with aplastic anemia typically get iron overload , sometimes requiring treatment for this, but patients with PNH ...

    Interview last updated 04/15/2015 - 9:39am.

  5. Making the Most of Office Visits with Your Specialist

    ... transfusions, and prevents and treats infections and iron overload . Nurses typically focus on the important topics of pain, side ...

    Interview last updated 10/14/2015 - 9:05am.

  6. Clinical Trials Report for April 2014

    ... Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study (TELESTO) The primary purpose of this study ... syndromes (low/int-1 risk) and transfusional iron overload . This study is being conducted in 187 sites across the U.S. ...

    Page last updated 04/18/2014 - 3:36pm.

  7. Overlap Syndromes: When PNH Appears with Aplastic Anemia or MDS

    ... mind is that patients with aplastic anemia typically get iron overload , sometimes requiring treatment for this, but patients with PNH ...

    Interview last updated 05/14/2015 - 1:53pm.

  8. Clinical Trials Report for November 2014

    ... in patients with AML and high risk MDS and chronic iron overload from blood transfusions. Deferasirox has been developed as an ...

    Page last updated 10/30/2014 - 9:42am.

  9. Clinical Trials Report for October 2014

    ... in patients with AML and high risk MDS and chronic iron overload from blood transfusions. Deferasirox has been developed as an ...

    Page last updated 09/30/2014 - 10:05am.